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Many small molecules and monoclonal antibodies blocking the activity of Epidermal Growth factor receptor (EGFR) have been
developed and have shown clinical activity in patients with non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal
cancer (CRC), and are in clinical development for a range of other solid tumors. The toxicity proﬁle of such agents is characterized
by a typical pattern of cutaneous reactions. In this paper we reviewed the current available data regarding the clinical signiﬁcance
of skin reaction due to EGFR targeted agents. We show that skin toxicity can be considered as predictive marker of response to
such drugs and that it is not disease speciﬁc; however its potential prognostic value is still to be proven.
Copyright © 2009 Monica Giovannini et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Receptors with kinase activity, which are involved in the
transmission of pleiotropic proliferation signals, seem to be
very promising targets for cancer treatments. Many small
molecules or monoclonal antibodies that can block the
activity of distinct sets of kinases are now available. Agents
that target the epidermal growth factor receptor (EGFR)
have demonstrated clinical activity in patients with nonsmall
cell lung cancer (NSCLC), pancreatic cancer, and colorectal
cancer (CRC), and are in clinical development for a range of
other solid tumors [1–4]. However, the tolerability proﬁle of
EGFR inhibitors (EGFRIs) is impacted by a unique group of
cutaneous reactions [5, 6]. Some of these skin events seem
to be related to clinical outcomes and survival and could
potentially be useful as surrogate markers for treatment
eﬃcacy [7]. We review the current available data regarding
the clinical signiﬁcance of skin reaction due to EGFR
targeted agents and its correlation with response to such
therapies.
EGFR. T h eh u m a ne p i d e r m a lg r o w t hf a c t o rr e c e p t o r
(HER1/EGFR) is a transmembrane glycoprotein of the
tyrosine kinase growth factor family that is expressed in
many normal human tissues and several tumors such as
colorectal (65–75%), head and neck (90%), and lung (60%–
90%) carcinomas [8]. Activation of EGFR by ligands, such
as EGF, leads to receptor dimerization and activation of
intrinsic tyrosine kinase (TK) activity. This activates down-
stream signaling pathways, including the mitogen-activated
protein kinase (MAPK) and the phosphatidylinositol-3-OH
kinase (PI3K/Akt) pathway, modulating gene transcription
and protein translation and ultimately stimulating tumor-
cell proliferation, migration, adhesion and angiogenesis and
inhibiting apoptosis [9]. Overexpression has been correlated
to uncontrolled cell growth, proliferation, angiogenesis and
metastases.Itisastrongprognosticfactorasitcorrelateswith
increased metastasis, reduced survival, and a poor outcome
[10].
EGFR Targeted Agents: See Table 1. Two main classes of
EGFR targeted agents have been developed so far: mon-
oclonal antibodies (mAb) which block the extracellular
domain of the receptor preventing ligand-dependent acti-
vation and downstream signalling and small molecule
inhibitors (TKI) orally administered, low molecular weight
compounds directed against the intracellular tyrosine kinase2 Journal of Oncology
domainblockingtheintracytoplasmicATP-bidingsiteonthe
receptor, preventing downstream signal transduction [11].
Cetuximab is a chimeric IgG1 mAb that is currently
approved in combination with irinotecan in the EU and
USA for EGFR-expressing metastatic CRC in patients who
are refractory to irinotecan-based chemotherapy, and as
monotherapy in the USA in patients who are intolerant
to irinotecan-based chemotherapy. It is also approved for
locally or regionally advanced head and neck squamous cell
carcinoma (HNSCC) in combination with radiation therapy
in the EU and USA, and metastatic or recurrent HNSCC that
is refractory to platinum-based therapy, in the USA [10, 12].
The TKI Geﬁtinib is also currently approved in the USA
as a third-line option for patients with NSCLC, but with
restrictions. Although this accelerated approval is based on
the results of a randomized phase II trial, data from a
phase III conﬁrmatory trial failed to show a survival beneﬁt.
As a result, the use of geﬁtinib is at present restricted to
patients currently or previously beneﬁting from it, and to
patients enrolled in clinical studies in the USA In addition,
it is currently approved for the treatment of inoperable or
recurrent NSCLC in Japan and several other Asian countries
[13, 14].
Erlotinib, another EGFR TKI, is currently approved in
the EU and USA as monotherapy for the treatment of
patients with locally advanced or metastatic NSCLC after
failure of at least one prior chemotherapy regimen. It is
also currently approved, in both regions, for the ﬁrst-line
treatment of patients with locally advanced, unresectable
or metastatic pancreatic cancer, in combination with gem-
citabine [15, 16].
Bevacizumab is the ﬁrst vascular endothelial growth
factor-targeted agent shown to increase survival in patients
receiving ﬁrst- and second-line intravenous 5-FU-based
chemotherapy for the treatment of metastatic colorectal
cancerand recently it has been approved also in combination
with carboplatin and paclitaxel, for ﬁrst-line treatment of
patients with unresectable, locally advanced, recurrent or
metastatic nonsquamous, nonsmall cell lung cancer and in
combination with paclitaxel for the treatment of patients
who have not received chemotherapy for metastatic HER2-
negative breast cancer [17, 18].
Panitumumab, a human IgG2 mAb, is currently
approved in the USA for EGFR-expressing, metastatic CRC
with disease progression on or following ﬂuoropyrimidine-,
oxaliplatin-, and irinotecan-containing chemotherapy regi-
mens [19, 20].
Most Common Skin Toxicities: See Table 2. The blockade of
the receptor in skin and appendages leads to various cuta-
neous reactions, occurring, on average, in >50% of patients
who receive treatment [21]. EGFRI-associated skin rash
appearstobedosedependent[22]and,ingeneral,tendstobe
morefrequentandofhighergradewithmAbsthanwithTKIs
[23]. However, the similar spectrum of events observed with
both mAbs and TKIs suggests that dermatologic toxicities
are likely to be a class eﬀect of these agents. A range of
adverse cutaneous reactions with variable severity have been
described so far. Xerosis (dry skin), pruritus, nail/periungual
alterations (usually manifested as paronychia), regulatory
abnormalities of hair growth (usually manifested as alopecia
of the scalp and trichomegaly of the eyelashes/hypertrichosis
of the face), and telangiectasia (dilatation of capillaries and
small blood vessels and hyperpigmentation) have all been
observed [24, 25]. The most commonly reported toxicity
is a papulopustular reaction. This usually develops on the
face and/or upper trunk and, in a majority of cases, peaks
in severity during the ﬁrst 1-2 weeks of therapy, stabilizing
during the following weeks. More speciﬁcally, the rash
commonly develops in the following phases: sensory distur-
bance with erythema and edema (week 0-1), papulopustular
eruption (weeks 1–3), crusting (weeks 3–5), and ending with
erythematotelangiectasias (weeks 5–8) [26].
Pathogenesis of Skin Toxicity. Mechanisms underlying
EGFRI-associated skin toxicities are far to be fully
characterized; however, interference with the follicular
and interfollicular epidermal-growth signalling pathway
is considered critical. Within the epidermis, EGFR plays
a critical role, stimulating epidermal growth, inhibiting
diﬀerentiation, protecting against UV-induced damage,
inhibiting inﬂammation, and accelerating wound healing
[27]. EGFR is known to be expressed in epidermal
keratinocytes, sebaceous and eccrine glands, and hair follicle
epithelium [28], and the greatest expression occurs in
proliferating and undiﬀerentiated keratinocytes, which are
located in the basal and suprabasal layers of the epidermis
and outer root sheath of the hair follicle [29]. Drug-
induced inhibition of EGFR is thought to alter keratinocyte
proliferation, diﬀerentiation, migration, and attachment
[30, 31] and this may help to explain the papulopustular
reaction and xerosis.
A mixed inﬂammatory inﬁltrate surrounding the upper
areas of the dermis (especially around follicles), follicular
rupture, and epithelial acantholysis have been described in
histological specimens taken from the skin of patients with
EGFRI-associated rash [32]. In normal skin, phosphorylated
EGFR is expressed in the basal and suprabasal layers,
and MAPK is observed in the basal layer. Treatment with
EGFRIs leads to abolishment of phosphorylated EGFR in all
epidermal cells and reduced expression of MAPK. Inhibition
of EGFR in basal keratinocytes leads to growth arrest
and premature diﬀerentiation. This is demonstrated by
upregulated expression of cyclin-dependent-kinase inhibitor
p27, keratin-1, and signal transducer and activator of
transcription-3 in the basal layer, markers of diﬀerentiation
that are normally only observed within the suprabasal layer
[33]. These events lead to release of inﬂammatory cell
chemoattractants that recruit leukocytes which are able to
release enzymes resulting in keratinocyte apoptosis, and
accumulation of these nonviable cells in the underlying
dermis results in additional cutaneous injury, which is
thought to account for a majority of symptoms, including
tenderness, papulopustules, and periungual inﬂammation
[24]. These changes may also favor bacterial overgrowth,
thus exacerbating inﬂammation, and have also been
observed in histological specimens from skin of treated
patients. Eventually, a decrease in thickness of the epidermisJournal of Oncology 3
Table 1: EGFR targeted agents.
Agent Class Indication Dose
Erlotinib TKI
-Locally advanced or metastatic NSCLC after at
least one prior chemotherapy regimen 100–150mg/day cancer
-Locally advanced or metastatic pancreatic cancer
in combination with gemcitabine
Geﬁtinib TKI
- As single agent Locally advanced or metastatic
NSCLC after at least platinum based and
docetaxel chemotherapy regimen (only in the
USA)
250mg/day
Catuximab mAb
- Locally or regionally advanced squamous cell
carcinoma of head and neck in combination with
radiotherapy 400mg/m2 initial dose
followed by 250mg/m2
weekly -A ss i n g l ea g e n tf o rr e c u r r e n to rm e t a s t a t i c
squamous cell carcinoma of head and neck after
failure of platinum-based chemotherapy
- As single agent in EGFR-expressing metastatic
colorectal carcinoma in case of intolerance to
irinotecan-based chemotherapy
- In combination with irinotecan in
EGFR-expressing metastatic colorectal carcinoma
in patients refractory to irinotecan-based
chemotherapy
Panitumumab mAb
- In EGFR-expressing metastatic colorectal
carcinoma in patients in progression on or
following ﬂiuoropyrimidine-, oxaliplatin-, and
irinotecan-based chemotherapy
6mg/kgivevery14days
Bevacizumab mAb
- Advanced colorectal cancer patients receiving
ﬁrst- and second-line intravenous 5-FU-based
chemotherapy for the treatment 5–15mg/kg/2 weeks
- In combination with carboplatin and paclitaxel,
for ﬁrst-line treatment of patients with
unresectable, locally advanced, recurrent or
metastatic nonsquamous, nonsmall cell lung
cancer
- In combination with paclitaxel for the treatment
of patients who have not received chemotherapy
for metastatic HER2-negative breast cancer.
is observed, demonstrating a thin stratum corneum that
lacks its characteristic basketweave conﬁguration (an
indication of abnormal diﬀerentiation) [33]. Interestingly, it
has been shown, in patients who have received radiotherapy
prior to EGFRI administration, that areas of skin having
undergone prior irradiation tend not to develop a rash
during erlotinib therapy [34]. This is thought to be a result
of depletion of EGFR-expressing cells or alterations in the
microvasculature in the skin covering irradiated areas.
Reviewing the existing literature on this topic, we previously
observed that in the sequential approach, when radiotherapy
is followed by EGFRI, no synergic/additive eﬀect between
radiotherapy and EGFRI occurs, as conversely observed
with the concomitant approach; such an eﬀect seems to be
detrimental, inducing a decrease in expression and activity
of EGFR. Moreover this eﬀect seems to be milder if EGFRI
is administered immediately after radiotherapy (by 3 weeks)
and much stronger when administered after a longer time
from radiotherapy [35].
2. CorrelationbetweenSkin Toxicityand
Response to EGFRTargeted Therapies
2.1. Cetuximab. In colorectal, pancreatic, and head and neck
cancer patients treated with cetuximab a correlation between
skinrashandoutcomehasbeenclearlydescribed,aboveallin
colorectalcancersettingwherecetuximabhasbeenusedfora
long time as standard treatment option in advanced disease.
ColorectalCancer. IntheOPUSstudy,aphaseIIrandomized
trial, 337 patients with untreated EGFR expressing advanced
colorectal cancer not respectable with curative intent have
been randomized between FOLFOX4 and FOLFOX plus
Cetuximab [36]. Median time to rash onset was 21 days.
A correlation between response rate and skin toxicity was
observed: 13% of patients with no skin toxicity responded
versus 42.2% if G1, 53.2% if G2, and 66.7% if G3-4.
In the phase III randomised Crystal Study 1217,
EGFR expressing advanced colorectal cancer patients were4 Journal of Oncology
Table 2: Most common skin toxicities.
Adverse event Frequency Description
Rash 60–80%
Monomorphous erythematous maculopapular,
follicular, or pustolar lesions which may be
associated with pruritus/tenderness
Paronychia and ﬁssuring 6–12%
Painful periungual granulation-type or friable
pyogenic granuloma-like changes, associated with
erythema, swelling, and ﬁssuring of lateral
nailfolds and/or distal ﬁnger tufts
Hair changes 5–6%
Alopecia and curlier, ﬁner and more brittle hair
on scalp and extremities; trychomegalia and
curling of eyebrows and hypertrichosis of the face
Dry skin 4–35% Diﬀuse ﬁne scaling
Mucositis 2–36%
Mild to moderate mucositis, stomatitis, and
aphthous ulcers
Hypersensitivity reactions 2–3% Flushicg, urticaria, and anaphylaxis
randomized to FOLFIRI plus Cetuximab versus FOLFIRI
[37]. Overall a slight beneﬁt in terms of overall response
rate and progression free survival Cetuximab was achieved
in the combination arm (P = .0 5 ) ;h o w e v e r ,g r e a t e rt h es k i n
toxicity higher the progression free survival, despite the lack
of data regarding the correlation between rash and overall
response rate and survival.
In2004Saltzetal.publishedaphaseIIopen-labelclinical
trial in metastatic EGFR expressing colorectal cancer treated
withCetuximabafteratleastonepriorlineofchemotherapy;
57 patients were enrolled [38]. A clear correlation between
outcome, in terms of median survival, and severity of skin
toxicity was observed (P = .02): 1.9 months if G0 versus 9.5
months if G3 skin toxicity. In the BOND study 329 EGFR
expressing advanced colorectal cancer patients after one
prior line of treatment were randomized to Cetuximab plus
Irinotecan versus Cetuximab [39]. Better response rate and
survivalwereachievedinthecombinationarm(22.9%versus
10.8%; 8 months versus 6.9 months, resp.). In particular, the
greater the skin toxicity the better response and survival, in
both arms. In fact, response rates in the 2 arms were 6.3%
versus 0% if no skin toxicity, 25.8% versus 12.9% if any
grade was considered and 33.6% versus 20% if only G ≥ 2
was considered; all the correlations were statistically highly
signiﬁcant.AnylevelofEGFRexpressionseemedtobelinked
to an equal chance of response to treatment. Regarding
this aspect, Saltz et al. reported in JCO that cetuximab
shows activity in colorectal cancer patients with tumors
that do not express the epidermal growth factor receptor
by immunohistochemistry [40]. Sobrero et al. presented at
AACR in 2007 the EPIC study, a multicenter, open-label,
phase III study in which 1,298 colorectal patients in II line of
treatment(afteroxaliplatin-based therapy) were randomized
to Cetuximab plus Irinotecan versus Irinotecan [41]. A
correlation between grade of skin toxicity and outcome was
reported:mediansurvivalwas5.8monthsifG0,11.7months
if G1-2, and 15.6 months if G3-4. In the NCIC CO.17 phase
III randomized study advanced colorectal cancer patients
who failed all recommended therapies were randomized to
Cetuximab versus best supportive care [42]. Better response
rate, progression free survival and survival were achieved in
the Cetuximab arm; skin toxicity was correlated to better
outcome: overall survival was 2.6 months if G0, 4.8 if G1 and
8 . 4i fG 2( P<. 001).
T h eE V E R E S Ts t u d yi sap h a s eI / I Is t u d yi nw h i c h1 6 6
Irinotecan refractory advanced colorectal cancer patients
after 3 weeks of treatment with Irinotecan plus Cetuximab
were randomized on the basis of skin toxicity: if G <
2 patients were randomized to classic Cetuximab dose
versus Cetuximab dose escalation performed every 2 weeks
until skin toxicity grade > 2[ 43]. Dose escalation arm
showed better response rate, disease control rate, duration
of response, progression free survival and median survival
compared to classic schedule.
Pancreatic Cancer. Xiong et al. published in JCO a phase II
study with the combination of Gemcitabine plus Cetuximab
as ﬁrst line treatment in 41 advanced pancreatic cancer
patients [44]. Higher skin toxicity was associated with better
outcome in terms of median survival (2.3 months if G0, 5.7
if G1, 8 if G2 and 13.9 if G3; P = .0007).
Head and Neck Cancer. A retrospective study was conducted
in 211 patients treated with Cetuximab and radiotherapy
after failure with Cisplatinum-based chemotherapy [45].
Better outcome in terms of survival was achieved in “the
prominent” rash group (Grade 2–4) compared to “the
minimal” rash group (G0-1): median survival was 56.7
months and 24.4 months, respectively, 3-year survival rate
was 65% versus 42%, respectively.
2.2. Geﬁtinib. In nonsmall cell lung cancer and head & neck
cancer patients treated with geﬁtinib a correlation between
skin rash and outcome has been reported.Journal of Oncology 5
Non Small Cell Lung Cancer. The IDEAL trials 1 and 2
were carried on to explore safety and eﬃcacy of Geﬁtinib
(250mg/day versus 500mg/day) in pretreated advanced non
small cell lung cancer patients (as 1st and 2nd line in
IDEAL 1 and as 2nd and beyond in IDEAL 2) [46, 47].
No diﬀerence was registered between the 2 dosages in both
studies in terms of outcome. The occurrence of early onset
skin toxicity in patients who survived at least 28 days was
analysed retrospectively: 67% of patients who ultimately
responded did not experience skin toxicity by day 24; 25% of
patients who ultimately responded did not have skin toxicity
by day 28. There was no statistically signiﬁcant diﬀerence in
the objective response rate between those with or without
early onset skin toxicity. In the Geﬁtinib Expanded Access
Program patients showing skin toxicity performed better in
terms of survival compared to those without skin toxicity
(10.8 versus 4 months, P = .0001) [48].
Head and Neck Cancer. Geﬁtinib was administered to 52
pretreated Head and Neck cancer patients in a phase II trial;
skin toxicity was associated with better median survival (11.1
versus 5.3 months, P = .001) compared to patients without
skin toxicity [49].
2.3. Erlotinib. Also in non small cell lung cancer, pancreatic
and head& neck cancerskin rashseemsto be associated with
better outcome has been reported in patients treated with
erlotinib.
Non Small Cell Lung Cancer. In the BR21 trial advanced
nonsmall cell lung cancer patients after one or two lines of
therapy were randomized to erlotinib versus placebo [50].
In 485 patients in erlotinib arm skin rash occurred in 75%
[G1-2 66%, G3 8%, G4 < 1%), median time of onset was 8
days(1–113),10%ofpatientsneededdosereductionbecause
of skin toxicity, in 7% of patients dose reduction due to skin
toxicitylasted>7days,in3%ofpatients >14days.Response
rate was higher in patients with at least G2 skin toxicity
(complete/partial response was 13% if G ≥ 2 versus 10% if
G1 versus 0% if G0; complete/partial response/stable disease
was 60% if G ≥ 2 versus 50% if G1 versus 16% if G0; all the
correlations were statistically signiﬁcant). Similarly median
survival was 11.1 months if G ≥ 2 versus 7.1 months if G1
versus 3.3 months if G0 (P<. 001) and progression free
survivalwas4monthsifG ≥ 2versus3.2monthsifG1versus
1.7 months if G0 (P<. 001). In the multivariate analysis
gender, age, race, histology, performance status, smoking
status, prior weight loss, EGFR status measured by IHC,
gene copy number by FISH, mutational status for EGFR
and KRAS and time from initial diagnosis were included.
A correlation between skin toxicity and progression free
survival was observed (HR 0.51 if G1 P<. 001, HR 0.35 if
G ≥ 2 P<. 001); similarly a strong correlation between skin
toxicity and survival (HR 0.51 if G1 P<. 001, HR 0.34 if
G ≥ 2 P<. 001).
Pancreatic Cancer. In PA.3 trial 254 patients with locally
advanced or metastatic pancreatic cancer were randomized
to erlotinib plus gemcitabine versus gemcitabine alone [50].
Skin rash occurred in 71% (G 1-2 66%, G3 3%, G4 2%);
median time of onset was 10 days (10–44 days), 2% of
patients needed dose reduction because of skin toxicity, in
5% of patients dose reduction due to skin toxicity lasted >
7 days, in 3% of patients the interruption was permanent.
Poor performance status was inversely correlated to skin
toxicity incidence (P = .0 1 ) .R e s p o n s er a t ew a sh i g h e r
in patients with at least G2 skin toxicity (complete/partial
response was 15% if G ≥ 2v e r s u s7 %i fG 1v e r s u s6 %i fG 0 ;
complete/partial response/stable disease was 74% if G ≥ 2
versus 58% if G1 versus 49% if G0; all the correlations were
statistically signiﬁcant). Similarly median survival was 10.8
months if G ≥ 2 versus 5.7 months if G1 versus 5.4 months if
G0 (P<. 001, P = .5, P<. 001) and progression free survival
was 6.5 months if G ≥ 2 versus 3.6 months if G1 versus 3.1
months if G0 (P<. 001). In the multivariate analysis gender,
age, race, performance status, prior chemotherapy, baseline
pain score, baseline albumin were included. A correlation
between skin toxicity and progression free survival if G ≥ 2
but not for milder grade was observed (HR 0.43 if G ≥ 2
versus G0 P<. 001, HR 0.98 if G1 P = .881); similarly
a strong correlation between skin toxicity and survival if
G ≥ 2 but not for milder grade (HR 0.46 if G ≥ 2v e r s u s
G0 P<. 001, HR 0.93 if G1 P = .66).
Head and Neck Cancer. Erlotinib was administered to 199
locally advanced and advanced head and neck treated with
nomorethanonepriortherapycancerinaphaseIItrial[51].
Median survival was higher if skin toxicity G ≥ 2o c c u r r e d
(224 days versus 120 days P = .045) but not in patients with
G1 skin toxicity (153 days P = .15).
2.4. Panitumumab. Very few data are currently available
regarding the correlation between skin toxicity and response
to treatment with panitumumab. A multicenter randomized
phase III trial was conducted in a population of heavily
pretreated patients with metastatic CRC [52]. In total, 463
patients with 1% or more EGFR expression in the tumor,
measurable disease, and radiological evidence of disease
progression during or within 6 months of most recent
chemotherapy were randomized to receive either 6mg/kg
panitumumab every 2 weeks plus best supportive care (BSC;
n = 231) or BSC alone (n = 232). Objective response rates
favored panitumumab plus BSC (10%) over BSC alone (0%;
P<. 0001). The median time to response was 7.9 weeks
and the median duration of response was 17.0 weeks. A
further64(28%)and24(10%)patientsinthepanitumumab
and BSC arms, respectively, experienced stable disease as
the best response. Similar activity was reported in patients
enrolled in the cross-over study. No diﬀerence in overall
survival was seen between the two arms, probably because
of the large number of patients assigned to BSC who crossed
over to the addition of panitumumab. In an exploratory
analysis, both progression-free survival and overall survival
rates were greater in patients with grade 2–4 skin toxic events
than in those with grade 1 events. Nineteen (86%) of 22
responders had skin toxic events of grade 2 or 3, whilst the6 Journal of Oncology
remaining3(14%)respondersexperiencedgrade1skintoxic
events.
2.5. Bevacizumab. Although exfoliative dermatitis has been
described as a side eﬀect in 19% of patients, skin rash
(type unspeciﬁed) has rarely been described in patients
following infusion of bevacizumab. Saiﬀ et al. have recently
reported the ﬁrst patient with colon cancer manifesting a
correlation between rash and a positive drug response with
bevacizumab [53]. A 49-year old male with T3 N1 M1 rec-
tal carcinoma received modiﬁed FOLFOX-6/bevacizumab,
which he tolerated very well except for grade 2 skin rash
related to bevacizumab. The rash continued to progress as
the serum carcinoembryonic antigen decreased signiﬁcantly.
Computed tomography and positron emission tomography
scan conﬁrmed response to FOLFOX/bevacizumab. There-
fore this rash was linked to bevacizumab administration and
correlated with response to therapy.
3. Conclusions
Skin toxicity is peculiarly associated with EGFR targeted
agents, both monoclonal antibodies, such as cetuximab, and
small molecules Tyrosin Kinase Inhibitors such as geﬁtinib
anderlotinib.Suchanalysisischallengingasnospeciﬁcgrad-
ing for skin toxicity is currently available and its evaluation
is often “clinician dependent.” Despite this potential bias an
association between skin toxicity and outcome to treatment
has been observed in most cases. It seems not to be disease
speciﬁc as it occurs in patients treated with EGFR targeted
therapies for colorectal cancer, pancreatic cancer, head &
neck cancer and non small cell lung cancer. Moreover and
more important its occurrence is clearly predictive of treat-
ment outcome and its severity is expression of the beneﬁt
gainfromsuchtherapies,independentlyfromEGFRtargeted
agent, line of treatment and chemotherapy associated with
EGFR inhibitors. Hence, skin toxicity can be considered a
predictive marker, surrogate of activity and eﬃcacy of EGFR
targeted therapies. In fact, skin toxicity can be seen as a
matter of pharmacodynamics; it can be considered a marker
of systemic drug concentration and consequently of drug
activity, independently from tumor histology. Moreover the
diﬀerence in severity of skin toxicity due to monocloclonal
antibodies or small molecules can be explained by diﬀerent
pharmacodynamics factors, such as transporter proteins, for
example, ABCG2 (55), which can interfere with intestinal
absorption of TKI. Its potential prognostic value is still to
be proven. Prior identiﬁcation of patients more likely to
develop skin toxicity and thus to beneﬁt from EGFR targeted
therapies remains a key issue. Moreover, a speciﬁc scale
measuring not only rash intensity but also the impact on
aesthetics and functionality has to be developed in order to
help physicians in the decision making process and patient
toxicity management. Clinicians have been getting more and
more used to managing skin toxicity due to EGFR targeted
agents; however it remains a big issue for the patients as it
can interfere dramatically with their social life, also because
of the lack of standard treatment guidelines.
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